Also found in: Wikipedia.


A nonionic structural analog of gadolinium DPTA; used as a paramagnetic contrast medium in magnetic resonance imaging.
References in periodicals archive ?
Also, Group II gadolinium-based agents, such as gadoteridol and gadobenate dimeglumine, should be used rather than Group I agents like gadodiamide and gadopentatate dimeglumine, which are associated with the greatest number of NSF cases.
Closely related diagnostic agents are gadobenate dimeglumine (MultiHance), gadodiamide (Omniscan), gadofosveset (Ablavar), gadopentetate dimeglumine (Magnevist), gadoteridol (Prohance), and gadoversetamide (OptiMARK).
Patients At higher risk * Patients with CKD 4 and 5 (GFR < 30 ml/min) * Patients on dialysis * Patients with acute kidney insufficiency At lower risk * Patients with CKD 3 (GFR 30 - 59 ml/min) Not at risk of NSF * Patients with stable GFR > 60 ml/min) Highest risk of NSF Gadopentetate dimeglumine (Magnevist plus generic products) Gadodiamide (Omniscan) Gadoversetamide (Optimark) Recommendations for These agents are CONTRA-INDICATED high-risk group in: * patients with CKD 4 and 5 (GFR <30 ml/min), including those on dialysis * acute renal insufficiency * pregnant women * neonates These agents should be used with CAUTION in: * patients with CKD 3 (GFR 30 - 60 ml/min) * There should be at least 7 days between 2 injections.
Brain metastases--comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging.
She had the injection of Omniscan - also known as gadodiamide - at Glasgow's Gartnavel Hospital in September 2006.
Patient 5 had received gadodiamide (Omniscan, GE Healthcare, Waukesha, Wisconsin), whereas the other 5 patients each had received gadopentetate dimeglumine (Magnevist, Bayer HealthCare Pharmaceuticals, Montville, New Jersey) as intravenous contrast during magnetic resonance studies.
In the large majority of cases, the product used for MRI was gadodiamide (OMNISCAN(R)), in a smaller number of cases gadopentetate dimeglumine (MAGNEVIST(R)) or gadoversetamide (4,5,8) (OPTIMARK(R)) were used.
Currently, there are four gadolinium-based contrast agents available commercially in the U5: gadodiamide (Omniscan; Amersham Health), gadopentetate dimeglumine (Magnevist; Schering), gadoversetamide (OptiMARK; Mallinckrodt Medical), and gadoteridol (Prohance; Bracco).
Contrast venography was performed with two 7 cc hand injections of gadodiamide (Omniscan, 0.
As of February 1, 2008, there have been 190 biopsy-proven cases of NSF published in the peer-reviewed literature with the following associations: 157 gadodiamide (ONISCAN), 8 gadopentetate (MAGNEVIST), 3 gadoversetamide (Optimark), and 18 unspecified GBCA, and 4 confounded cases with >1 GBCA.
Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.